All In Biotech

BLA 125291 · Genzyme

Lumizyme

Alglucosidase Alfa · Iv (Infusion) · Hydrolytic Lysosomal Glycogen-specific Enzyme

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Dec 30, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

May 24, 2010

Approved uses

2

Original approval plus efficacy supplements

Registered trials

30

6 Phase 3, 2 recruiting

FAERS reports

2,436

921 serious, 118 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS, IMMUNE-MEDIATED REACTIONS, and RISK OF ACUTE CARDIORESPIRATORY FAILURE WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS, IMMUNE-MEDIATED REACTIONS, and RISK OF ACUTE CARDIORESPIRATORY FAILURE See full prescribing information for complete boxed warning. Hypersensitivity Reactions Including Anaphylaxis Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. Initiate LUMIZYME in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue LUMIZYME and immediately initiate appropriate medical treatment, including use of epinephrine. ( 5.1 ) Immune-Mediated Reactions Immune-mediated reactions presenting as...

What it is approved for

From the label in effect Jan 10, 2025.

LUMIZYME ® is a hydrolytic lysosomal glycogen-specific enzyme indicated for patients with Pompe disease (acid α-glucosidase [GAA] deficiency). LUMIZYME ® is a hydrolytic lysosomal glycogen-specific enzyme indicated for patients with Pompe disease (GAA deficiency). ( 1 )

Mechanism: Pompe disease (acid maltase deficiency, glycogen storage disease type II, GSD II, glycogenosis type II) is an inherited disorder of glycogen metabolism caused by the absence or marked deficiency of the lysosomal enzyme GAA. Alglucosidase alfa provides an exogenous source of GAA. Binding to mannose-6-phosphate receptors on the cell surface has been shown to occur via carbohydrate groups on the GAA molecule, after which it is internalized and transported into lysosomes, where it undergoes proteolytic cleavage that results in increased enzymatic activity. It then exerts enzymatic activity in...

Therapeutic areas: Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 1, 2014 Supplement 136 · Efficacy · priority review LabelReviewLetter
  • May 24, 2010 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
1 products under this application
  • LUMIZYME · ALGLUCOSIDASE ALFA 5MG/ML · POWDER, IV (INFUSION) · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Alglucosidase Alfa" as an intervention, any sponsor and status, largest first.

All 30 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • inappropriate schedule of product administration219
  • pyrexia179
  • off label use153
  • dyspnoea141
  • malaise105
  • fatigue100
  • pneumonia100
  • fall95
  • drug specific antibody present89
  • urticaria87
  • infusion related reaction83
  • rash83

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20091
20104
201124
201243
2013153
2014210
2015181
2016143
2017148
2018146
2019182
2020121
2021225
2022263
2023210
2024150
2025130
2026102

Recalls

1 FDA enforcement reports for this application.

  • Dec 8, 2015 · Class III · Terminated

    Labeling: Incorrect or Missing Lot and/or Exp Date

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lumizyme (Alglucosidase Alfa)

2024 spending

$13.2M

Beneficiaries

17

206 claims

Per beneficiary

$778,063

$967.39 per unit

View as table
YearSpending
2020$47,712,903
2021$49,935,206
2022$29,852,277
2023$18,626,215
2024$13,227,075

Part B: Lumizyme (Alglucosidase Alfa) · HCPCS J0221

2024 spending

$17.1M

Beneficiaries

31

429 claims

Per beneficiary

$552,042

2024 ASP limit $199.55 per unit

View as table
YearSpending
2020$62,106,435
2021$61,675,530
2022$41,371,331
2023$25,682,601
2024$17,113,296

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 42 on PubMed

Sponsor: Sanofi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.